Langerhans cell histiocytosis and hypercalcemia: clinical response to indomethacin.
OBJECTIVE
Hypercalcemia is a known complication of childhood malignancies but has never been reported to be associated with Langerhans cell histiocytosis (LCH) in a pediatric patient.


METHODS
We describe an infant with multisystem LCH who developed hypercalcemia on two occasions. After being placed on indomethacin, the hypercalcemia did not recur despite disease progression.


CONCLUSIONS
Hypercalcemia may complicate LCH. If it is demonstrated, indomethacin should be considered as a treatment.
McLean
T W
TW
Division of Pediatric Hematology-Oncology, Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115-6084, USA.
Pritchard
J
J
D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D017809:Fatal Outcome; D005500:Follow-Up Studies; D006646:Histiocytosis, Langerhans-Cell / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D006934:Hypercalcemia / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007213:Indomethacin / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D011859:Radiography; D013997:Time Factors
D016861:Cyclooxygenase Inhibitors; D007213:Indomethacin